Imaging endogenous dopamine competition with [11C]raclopride in the human brain
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
This study images dopamine release in response to a neurochemically specific challenge with the psychostimulant drug methylphenidate. Changes in synaptic dopamine induced by methylphenidate were evaluated with positron emission tomography and [11 C]raclopride, a D 2 receptor radioligand that is sensitive to endogenous dopamine. Methylphenidate significantly decreased striatal [11 C]raclopride binding. The decrease was variable and was negatively correlated with age. Mood and anxiety at baseline, were also correlated with methylphenidate‐induced DA changes. This strategy provides a tool to investigate the responsiveness of the dopamine system in the normal and diseased human brain and to investigate the neurochemical correlates of behavior. © 1994 Wiley‐Liss, Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Neurogenetic Adaptive Mechanisms in Alcoholism
Cloninger, C. R. (1987) · Science · doi:10.1126/science.2882604 · Cited by 2,234
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987) · Science · doi:10.1126/science.2820058 · Cited by 2,180
Cellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070 · cited 1×
“Dopamine (DA) is a neurotransmitter that plays a major role in movement, motivation, and reward (Koob and Bloom, 1988; Le Moal and Simon, 1991; Ritz et al., 1987; Wise, 1988).”
BackgroundAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationDOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442
Factors That Predict Individual Vulnerability to Amphetamine Self-Administration
Piazza, P. V., Deminière, J.-M., Le Moal, M., & Simon, H. (1989) · Science · doi:10.1126/science.2781295 · Cited by 1,351
Research works printed but not linked: 9
- Davis K. L., 1991, Dopamine in schizophrenia: a review and reconceptualization. Am. J, Psychiatry, 148, 1474
- Ekman G., 1967, The measurement of subjective reactions, Forsvarsedicine, 33, 27
- Ferris R., 1972, A comparison of the capabilities of isomers of amphetamine, deoxyperadrol and methylphenidate to inhibit the uptake of catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta, J. Pharmacol., 14, 47
- Innis R. B., 1993, SPECT imaging demonstrates loss of striatal dopamine transporters in parkinson's disease, J. Nucl. Med., 34, 31
- Joseph J. A., 1990, The striatum, a microcosm for the examination of age‐related alterations in the CNS: a selected review. Rev. Biolog. Res, Aging, 4, 181
- Kandel D. B., 1989, Cessation of illicit drug use in young adulthood. Arch. Gen, Psychiatry, 46, 109
- Logan J., 1993, The effects of changes in blood flow on the distribution volume of [11C]raclopride binding, J. Nucl. Med., 34, 200
- Raichle M. E., 1983, Brain blood flow measured with intravenous H2 15O, J. Nucl. Med., 24, 790
- Wong D. F., 1992, C‐11 WIN 35,428 imaging of the dopamine transporter site in living human brain, J. Nucl. Med., 33, 964
Cited by
Items 201–300 of 379
Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders
Auriel, E., Hausdorff, J. M., & Giladi, N. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318170576c · Cited by 46
Addiction and imaging of the living human brain
Gatley, S. J., & Volkow, N. D. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00069-6 · Cited by 42
Self-citationMolecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
Hirao, K., Pontone, G. M., & Smith, G. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.010 · Cited by 40
New developments of brain imaging for Parkinson's disease and related disorders
Piccini, P. P., & Brooks, D. J. (2006) · Movement Disorders · doi:10.1002/mds.20845 · Cited by 47
Dopamine release in human associative striatum during reversal learning
Grill, F., Guitart‐Masip, M., Johansson, J. J., Jonasson, L. S., Axelsson, J., Nyberg, L. H., & Rieckmann, A. (2024) · Nature Communications · doi:10.1038/s41467-023-44358-w · Cited by 38
PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics
Stevens, T., Sangkuhl, K., Brown, J. T., Altman, R. B., & Klein, T. E. (2019) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000376 · Cited by 45
Biomarkers for the Development of New Medications for Cocaine Dependence
Bough, K. J., Amur, S., Lao, G., Hemby, S. E., Tannu, N. S., Kampman, K. M., Schmitz, J. M., Martínez, D., Merchant, K., Green, C., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.210 · Cited by 40
“The D2 receptors are imaged before and after the administration of a stimulant, which causes the dopamine neurons to release dopamine (Breier et al, 1997; Laruelle et al, 1997; Volkow et al, 1994).”
Backgroundde Haes, J. I. U., Maguire, R. P., Jager, P. L., Paans, A. M. J., & den Boer, J. A. (2007) · Human Brain Mapping · doi:10.1002/hbm.20293 · Cited by 35
“In our study we were interested in the effect of MP on changes in relative regional CBF. Previous studies have shown that the behavioral state of the subject may influence the MP-induced effects on DA release or neuronal activity [Volkow et al., 1994, 1998].”
ResultMoerlein, S. M., Perlmutter, J. S., Markham, J., & Welch, M. J. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199708000-00002 · Cited by 37
PET Studies on the Function of Dopamine in Health and Parkinson's Disease
Brooks, D. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07460.x · Cited by 40
Trifilieff, P., & Martínez, D. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00044 · Cited by 41
“For example, in healthy human volunteers, the administration of a psychostimulant produces a decrease in [11C]raclopride binding (∆BPND) of 15–20% (Volkow et al., 1994; Drevets et al., 2001; Martinez et al., 2003; Munro et al., 2006), but in cocaine abusers the decrease in [11C]raclopride binding…”
BackgroundStriatal Dopamine D2/D3 Receptor Availability Varies Across Smoking Status
Wiers, C. E., Cabrera, E. A., Tomasi, D. G., Wong, C., Demiral, Ş. B., Kim, S. W., Wang, G., & Volkow, N. D. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.131 · Cited by 35
“Thus, comparison of [11C] raclopride’s binding after placebo from that after a challenge with a stimulant drug such as methylphenidate (MP) serves as an estimate of DA release (Volkow et al, 1994).”
InfluentialSelf-citationGatley, S. J., Ding, Y., Volkow, N. D., Chen, R., Sugano, Y., & Fowler, J. S. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00233-b · Cited by 35
Self-citationD2 receptor binding in dopa‐responsive dystonia
Künig, G., Leenders, K. L., Antonini, A., Vontobel, P., Weindl, A., & Meinck, H. M. (1998) · Annals of Neurology · doi:10.1002/ana.410440509 · Cited by 34
The role of dopamine in cognition: evidence from functional imaging studies
Rémy, P., & Samson, Y. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312002-00007 · Cited by 34
Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders
Kugaya, A., Fujita, M., & Innis, R. B. (2000) · Annals of Nuclear Medicine · doi:10.1007/bf02990472 · Cited by 39
Neurobiology of Learning and Memory
Volkow, N. D., Fowler, J. S., Wang, G., & Goldstein, R. Z. (2002) · Cited by 33
Self-citationMR-PET Image Coregistration for Quantitation of Striatal Dopamine D2 Receptors
Wang, G.-J., Volkow, N. D., Levy, A. V., Fowler, J. S., Logan, J., Alexoff, D., Hitzemann, R. J., & Schyler, D. J. (1996) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199605000-00020 · Cited by 33
Self-citationPET Imaging Studies in Drug Abuse
Fowler, J. S., & Volkow, N. D. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809028936 · Cited by 35
Self-citationAbsolute Quantification by Positron Emission Tomography of the Endogenous Ligand
Delforge, J., Bottlaender, M., Pappatà, S., Loc’h, C., & Syrota, A. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200105000-00016 · Cited by 34
“…groups have provided evidence of a significant influence of the ELs on the positron emission tomography (PET) data in several ligand-receptor interaction systems (Carson et al., 1997; Dewey et al., 1992; Koepp et al., 1998; Laruelle et al., 1997a,b; Price et al., 1998; Volkow et al., 1994, 1996).”
BackgroundKasparbauer, A., Rujescu, D., Riedel, M. J., Pogarell, O. M., Costa, A. C. L., Meindl, T., la Fougère, C., & Ettinger, U. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.240 · Cited by 31
“MPH indirectly elevates extracellular concentrations of DA levels in striatal (Volkow et al, 1994) and extrastriatal (Montgomery et al, 2007) regions by blockage of DA transporters (DAT), while additionally blocking noradrenaline transporters.”
BackgroundNeuroethical issues in pharmacological cognitive enhancement
Mohamed, A. D. (2014) · Wiley Interdisciplinary Reviews Cognitive Science · doi:10.1002/wcs.1306 · Cited by 35
PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders
Červenka, S. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.03.007 · Cited by 31
Development of imaging agents for the dopamine transporter
Carroll, F. I., Scheffel, U., Dannals, R. F., Boja, J. W., & Kuhar, M. J. (1995) · Medicinal Research Reviews · doi:10.1002/med.2610150503 · Cited by 30
Brody, A. L., London, E. D., Olmstead, R. E., Allen-Martinez, Z., Shulenberger, S., Costello, M. R., Abrams, A. L., Scheibal, D., Farahi, J. B., SHOPTAW, S. J., et al. (2010) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.06.004 · Cited by 30
Agonist‐dependent internalization of D2 receptors: Imaging quantification by confocal microscopy
Goggi, J., Sardini, A., Egerton, A., Strange, P. G., & Grasby, P. M. (2007) · Synapse · doi:10.1002/syn.20360 · Cited by 33
“Thus, the BP of [11C]raclopride or [123I]IBZM is decreased by drugs that increase extracellular DA concentration (Innis et al., 1992; Laruelle et al., 1995; Volkow et al., 1994) and increased by drugs that decrease DA concentration (Ginovart et al., 1997; Laruelle et al., 1997).”
BackgroundMethodPotential of [11C]DASB for measuring endogenous serotonin with PET: binding studies
Lundquist, P., Wilking, H., Höglund, A. U., Sandell, J., Bergström, M., Hartvig, P., & Långström, B. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.12.001 · Cited by 31
Dopamine activation in Neuroticism as measured by spontaneous eye blink rate
Barbato, G., della Monica, C., Costanzo, A., & Padova, V. D. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.08.004 · Cited by 27
Rice, O. V., Gatley, S. J., Shen, J., Huemmer, C. L., Rogoz, R., DeJesus, O. T., Volkow, N. D., & Gifford, A. N. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00287-1 · Cited by 28
“%) in the binding of [ 11 C]raclopride and or of [ 123 I]IBZM (Innis et al. 1992; Volkow et al. 1994; Laruelle et al. 1995; Carson et al. 1997; Laruelle et al. 1997; Volkow et al. 1999).”
BackgroundOpacka‐Juffry, J., Ashworth, S., Ahier, R. G., & Hume, S. P. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050063 · Cited by 31
“led to an approximately 8-fold increase in extracellular striatal DA, whereas the lower dose of L-DOPA resulted in only 60% increase in striatal DA. It has been known for several years that there is a competition between raclopride and endogenous dopamine and that radiolabelled raclopride can be displaced by elevated…”
Neural and Behavioral Endophenotypes in ADHD
del Campo, N., Müller, U., & Sahakian, B. J. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_200 · Cited by 31
Schabram, I., Henkel, K., Shali, S. M., Dietrich, C., Schmaljohann, J., Winz, O., Prinz, S., Rademacher, L., Neumaier, B., Felzen, M., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1560-14.2014 · Cited by 29
PET Neurochemical Imaging Modes
Placzek, M. S., Zhao, W., Wey, H., Morin, T., & Hooker, J. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.001 · Cited by 31
“As an example of these characteristics, an early report measured binding changes of [(11)C] raclopride in a bolus blocking study to detect changes in dopamine release following indirect pharmacologic challenge.(55) In this study, methylphenidate (0.”
Normandin, M. D., & Morris, E. D. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.046 · Cited by 27
“…Mach et al., 1997), cocaine (Mach et al., 1997; Volkow et al., 1999), methylphenidate (Mach et al., 1997; Spencer et al., 2006; Volkow et al., 1999; Volkow et al., 1994) and other drugs, as well as behavioral challenges such as videogaming (Koepp et al., 1998), gambling and monetary reward…”
Dopaminergic function and progression of Parkinson's disease: PET findings
Biju, G., & de la Fuente‐Fernández, R. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70833-8 · Cited by 31
Neurodegenerative movement disorders: the contribution of functional imaging
Piccini, P. P. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137538.84115.3c · Cited by 28
Imaging neurochemical endophenotypes: promises and pitfalls
Martínez, D., Broft, A. I., & Laruelle, M. A. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.3.223 · Cited by 28
Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder
Wang, G., Wiers, C. E., Shumay, E., Tomasi, D. G., Yuan, K., Wong, C., Logan, J., Fowler, J. S., & Volkow, N. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0421-x · Cited by 25
Self-citationUmesawa, Y., Matsushima, K., Atsumi, T., Kato, T., Fukatsu, R., Wada, M., & Ide, M. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04382-x · Cited by 27
“The medicines taken by eight ASD participants in the present study have been reported to mainly affect dopaminergic and noradrenergic neurotransmitter (Bymaster et al. 2002; Castellanos et al. 1996; Volkow et al. 1994).”
BackgroundSmith, G. S., Ma, Y., DHAWAN, V. M., Chaly, T., & Eidelberg, D. (2008) · Synapse · doi:10.1002/syn.20574 · Cited by 27
Parkinsonʼs disease: imaging update
de la Fuente‐Fernández, R., & Stoessl, A. J. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200208000-00012 · Cited by 24
Darcey, V. L., Guo, J., Chi, M., Chung, S. T., Courville, A. B., Gallagher, I., Herscovitch, P., Joseph, P. V., Howard, R., LaNoire, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.02.002 · Cited by 26
Demiral, Ş. B., Manza, P., Biesecker, E., Wiers, C. E., Kojori, E. S., McPherson, K. L., Dennis, E., Johnson, A., Tomasi, D. G., Wang, G., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03979-5 · Cited by 22
Self-citationAlbaugh, D. L., & Shih, Y. I. (2013) · Brain Connectivity · doi:10.1089/brain.2013.0193 · Cited by 29
“For example, using 11 C-raclopride displacement, an increase in dopamine concentrations in excess of 10% is required to visualize a change (Volkow et al., 1994).”
Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders
Slifstein, M., & Abi‐Dargham, A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.002 · Cited by 25
Luo, S. X., Martínez, D., Carpenter, K. M., Slifstein, M., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.04.030 · Cited by 22
Alvanzo, A. A. H., Wand, G. S., Kuwabara, H., Wong, D. F., Xu, X., & McCaul, M. E. (2015) · Addiction Biology · doi:10.1111/adb.12300 · Cited by 22
“…participants underwent two consecutive 90-minute PET scans with [11C]raclopride, a benzamide antagonist at the DA D2 and D3 receptors, which has previously been shown to be sensitive to stimulant-induced changes in brain DA concentration (Volkow et al. 1994; Endres et al. 1997; Laruelle 2000).”
MethodChiara, G. D. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00010 · Cited by 25
Zhou, X., Doorduin, J., Elsinga, P. H., Dierckx, R. A. J. O., de Vries, E. F. J., & Casteels, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.066 · Cited by 22
“Also, decreased levels of endogenous dopamine have been proposed to increase the binding of [11C]raclopride to D2Rs in PD patients, as both raclopride and dopamine have similar D2R affinities and thus compete for the binding site of the receptor (Ishibashi et al., 2010; Volkow et al., 1994).”
Kortekaas, R., Maguire, R. P., Cremers, T. I. F. H., Dijkstra, D., van Waarde, A., & Leenders, K. L. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200405000-00007 · Cited by 22
“The amphetamines d-amphet-amine, d-methamphetamine and d-methylphenidate cause an increase in dopamine concentration in the brain and a reduction in [ 11 C]raclopride binding (Dewey et al., 1993; Volkow et al., 1994; Tsukada et al., 1999).”
BackgroundDoudet, D. J., & Holden, J. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000093325.88757.92 · Cited by 23
Imaging the neurochemical brain in health and disease
Grasby, P. M. (2002) · Clinical Medicine · doi:10.7861/clinmedicine.2-1-67 · Cited by 21
Biochemical Correlates of Video Game Use: From Physiology to Pathology. A Narrative Review
Carpita, B., Muti, D., Nardi, B., Benedetti, F., Cappelli, A., Cremone, I. M., Carmassi, C., & Dell’Osso, L. (2021) · Life · doi:10.3390/life11080775 · Cited by 26
“These results suggest that video game playing may cause a DA release similar to the effects of psycho-stimulant drugs such as methylphenidate [115,116] and amphetamine [117].”
ResultReeves, S., Eggleston, K., Cort, E., McLachlan, E., Brownings, S., Nair, A., Greaves, S., Smith, A., Dunn, J., Marsden, P. K., et al. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4758 · Cited by 21
“, 2009b), and/or reduced competition due to lower endogenous dopamine levels (Volkow et al., 1994) in those of extreme age contributed to our findings.”
Tong, Z.-Y., Overton, P. G., & Clark, D. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199603)22:3<195::aid-syn1>3.0.co;2-7 · Cited by 189
Neural circuit selective for fast but not slow dopamine increases in drug reward
Manza, P., Tomasi, D. G., Kojori, E. S., Zhang, R., Kroll, D. S., Feldman, D. E., McPherson, K. L., Biesecker, C. L., Dennis, E., Johnson, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41972-6 · Cited by 20
“Therefore, decreases in [ 11 C] Raclopride binding following administration of a dopamine-boosting drug like MP are a suitable proxy for ‘ dopamine increases ’ 88,89 .”
Self-citationBrain imaging after neural transplantation
Politis, M., & Piccini, P. P. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84010-5 · Cited by 19
Norman, L. R., & Basso, M. R. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150309124820 · Cited by 22
Neuroreceptor Imaging in Psychiatry: Theory and Applications
Frankle, W. G., Slifstein, M., Talbot, P. S., & Laruelle, M. A. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(05)67011-0 · Cited by 29
Psychopharmacology -- in vivo neurochemistry and pharmacology
Grasby, P. M., Malizia, A. L., & Bench, C. J. (1996) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011564 · Cited by 19
Udo de Haes, J. I., Kortekaas, R., Van Waarde, A., Maguire, R. P., Pruim, J., & den Boer, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0193-2 · Cited by 18
Jayaram‐Lindström, N., Guterstam, J., Häggkvist, J., Ericson, M., Malmlöf, T., Schilström, B., Halldin, C., Červenka, S., Saijo, T., Nordström, A., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.79 · Cited by 19
Levodopa effects on [11C]raclopride binding in the resting human brain
BLACK, K. J., Piccirillo, M. L., Koller, J. M., Hseih, T., Wang, L., & Mintun, M. A. (2015) · F1000Research · doi:10.12688/f1000research.5672.1 · Cited by 19
Positron emission tomography imaging of transplant function
Brooks, D. J. (2004) · Neurotherapeutics · doi:10.1007/bf03206632 · Cited by 18
Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks
Marciano, S., Ionescu, T. M., Saw, R. S., Cheong, R. Y., Kirik, D., Maurer, A., Pichler, B. J., & Herfert, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122552119 · Cited by 18
In vivo imaging of the integration and function of nigral grafts in clinical trials
Politis, M., & Piccini, P. P. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00009-0 · Cited by 17
Shumay, E., Wiers, C. E., Kojori, E. S., Kim, S. W., Hodgkinson, C. A., Sun, H., Tomasi, D. G., Wong, C., Weinberger, D. R., Wang, G., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3155-16.2017 · Cited by 16
“DRD2 availability decreased with age in all three striatal ROIs (caudate F(1,90) 63.1, 2 0.43; putamen F(1,90) 67.3, 2 0.44; VS F(1,90) 38.8, 2 0.31; all p’s 0.0001), which is consistent with previous findings (Volkow et al., 2000; Ishibashi et al., 2009; Kim et al., 2011).”
ResultSelf-citationPET Measurement of rCBF in the presence of a neurochemical tracer
Converse, A. K., Barnhart, T. E., Dabbs, K., DeJesus, O. T., Larson, J. A., Nickles, R. J., Schneider, M. L., & Roberts, A. D. (2003) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2003.09.006 · Cited by 16
“E-mail address:akconverse@wisc.edu (A.K. Converse). placebo (de la Fuente-Fernández et al., 2001; Koepp et al., 1998; Volkow et al., 1994).”
Functional neuroimaging in Parkinson's disease
de la Fuente‐Fernández, R., Appel‐Cresswell, S., Doudet, D. J., & Sossi, V. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.554820 · Cited by 16
Neural effects of methylphenidate and nicotine during smooth pursuit eye movements
Kasparbauer, A., Meyhöfer, I., Steffens, M., Weber, B., Aydin, M., Kumari, V., Hurlemann, R., & Ettinger, U. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.07.012 · Cited by 15
“Major binding sites include striatal (Volkow et al., 1994) and extrastriatal dopamine transporters (Montgomery et al., 2007), but also noradrenalin transporters (Hannestad et al., AC C EP TE D M AN U SC R IP T 2010).”
BackgroundStudying molecular and cellular processes in the intact organism
Gheysens, O. S., & Gambhir, S. S. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7426-8_4 · Cited by 15
Translational PET applications for brain circuit mapping with transgenic neuromodulation tools
Boehm, M. A., Bonaventura, J., Gomez, J. L., Solís, Ó., Stein, E. A., Bradberry, C. W., & Michaelides, M. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173147 · Cited by 14
Daood, M., Peled‐Avron, L., Ben‐Hayun, R., Nevat, M., Aharon‐Peretz, J., Tomer, R., & Admon, R. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109190 · Cited by 15
Examining the role of dopamine in methylphenidate’s effects on resting brain function
Tomasi, D. G., Manza, P., Yan, W., Kojori, E. S., Demiral, Ş. B., Yonga, M.-V., McPherson, K. L., Biesecker, C. L., Dennis, E., Johnson, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314596120 · Cited by 14
“MP blocks the DAT (27), leading to increases in extracellular DA (31) that compete for binding to D 2/3 receptors with [ 11 C] raclopride (28).”
Self-citationGifford, A. N., Park, M. H., Kash, T. L., Herman, L. M., Park, E.-H., Gatley, S. J., & Volkow, N. D. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100000293 · Cited by 14
Self-citationPositron emission tomography radiochemistry
Mason, N. S., & Mathis, C. A. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00093-5 · Cited by 16
Hurd, Y. L., & Hall, H. (2005) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(05)80013-2 · Cited by 18
Brain dopamine receptor system is not altered in obesity: Bayesian and frequentist meta‐analyses
Pak, K., & Nummenmaa, L. (2023) · Human Brain Mapping · doi:10.1002/hbm.26534 · Cited by 13
“Both C11-Raclopride and F18-Fallypride, D2/D3 antagonists, have a similar affinity to D2 and D3 and compete with endogenous dopamine (Dunn et al., 2012; Volkow et al., 1994).”
BackgroundMach, R. H., Ehrenkaufer, R. L., Greenberg, J. H., Shao, L., Morton, T. E., Evora, P. H., Nowak, P. A., Luedtke, R. R., Cohen, D., & Reivich, M. (1995) · Synapse · doi:10.1002/syn.890190305 · Cited by 13
Koochesfahani, K. M., de la Fuente‐Fernández, R., Sossi, V., Schulzer, M., Yatham, L. N., Ruth, T. J., Blinder, S. A. L., & Stoessl, A. J. (2006) · Movement Disorders · doi:10.1002/mds.20857 · Cited by 13
Gatley, S. J., Gifford, A. N., Carroll, F. I., & Volkow, N. D. (2000) · Synapse · doi:10.1002/1098-2396(20001215)38:4<483::aid-syn14>3.0.co;2-w · Cited by 13
Self-citationNeuroreceptor Imaging of Stress and Mood Disorders
Kennedy, S. E., & Zubieta, J.-K. (2004) · CNS Spectrums · doi:10.1017/s1092852900009238 · Cited by 12
Positron Emission Tomographic Evidence of Similarity Between Obesity and Drug Addiction
Wang, G., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2003) · Psychiatric Annals · doi:10.3928/0048-5713-20030201-06 · Cited by 12
Self-citationDopamine Release in the Midbrain Promotes Anxiety
Calipari, E. S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.08.016 · Cited by 11
“This system has been a major focus of psychiatric disease research given the critical role it plays in mood disorders - including anxiety disorders - where its dysregulation has been linked to the expression of negative affective states in human and animal models (2,3).”
BackgroundKim, S. E., & Han, S. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009826 · Cited by 11
Neuropharmacology and Receptor Studies in the Elderly
MELTZER, C. C. (1999) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879901200307 · Cited by 11
Highlights of PET studies on chiral radiotracers and drugs at Brookhaven
Ding, Y., & Fowler, J. S. (2003) · Drug Development Research · doi:10.1002/ddr.10221 · Cited by 11
“It has been suggested that the stimulant appears to increase the level of extracellular dopamine in the frontal lobe of the brain [Butcher et al., 1991; Volkow et al., 1994; Zetterstrom et al., 1988] where it regulates attention and impulsivity.”
BackgroundSelf-citationSpecial Section: On Looking Inward
den Boer, J. A., Reinders, A. A. T. S., & Glas, G. G. (2008) · Theory & Psychology · doi:10.1177/0959354308089791 · Cited by 11
“…between subjective effects and changes in ligand binding (Drevets et al., 2001; Laruelle et al., 1995; Leyton et al., 2002; Martinez et al., 2003; Volkow et al., 1994, 1999), we assessed the subjective state of the participant before and after methylphenidate (MP) administration (Udo de Haes et…”
POSITRON EMISSION TOMOGRAPHY: Biomedical Research and Clinical Application
Wolf, A. P., & Fowler, J. S. (1995) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00278-3 · Cited by 11
Self-citationBeyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Royse, S. K., Lopresti, B. J., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15657 · Cited by 26
“Demonstration that preadministration of psychostimulant drugs could dramatically reduce the striatal in vivo binding of [11C]raclopride was shown for damphetamine, GBR12909, and methylphenidate (Dewey, Smith, Logan, Brodie, Fowler, & Wolf, 1993; Volkow et al., 1994).”
BackgroundInfluentialIn vivo snapshots of the dopaminergic synapse in small animals
Nikolaus, S., Beu, M., Wirrwar, A., Antke, C., & Müller, H.-W. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001693 · Cited by 10
Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies
Lamelle, M., & Abi‐Dargham, A. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.4/mlamelle · Cited by 10
Park, M., & Park, E. (2000) · Archives of Pharmacal Research · doi:10.1007/bf02975448 · Cited by 10
Effects of dopamine on the in vivo binding of dopamine d2 receptor radioligands in rat striatum
Moresco, R., Loc’h, C., Ottaviani, M., Guibert, B., Leviel, V., Mazière, M., Fazio, F., & Maziere, B. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00048-1 · Cited by 10
“Finally, the good responsiveness of [(11)C]raclopride to changes in extracellular dopamine make this tracer, so far, a unique candidate for the in vivo PET measurement of functional responsiveness of dopaminergic system to pharmacological challenges and the modulation of striatal dopamine release by GABAergic, choline…”
BackgroundMethodBrain connectivity changes to fast versus slow dopamine increases
Manza, P., Tomasi, D. G., Vines, L., Sotelo, D., Yonga, M.-V., Wang, G., & Volkow, N. D. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01803-8 · Cited by 9
“Therefore, decreases in [ 11 C]Raclopride binding following administration of a dopamine-boosting drug like MP are a suitable proxy for ‘ dopamine increases ’ [34, 35].”
Self-citationYan, W., Demiral, Ş. B., Tomasi, D. G., Zhang, R., Manza, P., Wang, G., & Volkow, N. D. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1693-24.2025 · Cited by 9
“Since MP reduces striatal D 2 R availability by increasing binding competition with [ 11 C]raclopride, as synaptic DA is increased (Volkow et al., 1994), the correlation between D 2 R availability audio 1.”
Self-citationMethylphenidate reduces orienting bias in healthy individuals
Peled‐Avron, L., Goren, H. G., Brande-Eilat, N., Dorman-Ilan, S., Segev, A., Feffer, K., Gvirts, H. Z., Levkovitz, Y., Barnea, Y., Lewis, Y. D., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121996884 · Cited by 9
“MPH blocks the dopamine transporter (DAT), thus increasing significantly the levels of extracellular dopamine in the striatum (Volkow et al., 1994).”
BackgroundVassena, E., Opstal, F. V., Goethals, I., & Verguts, T. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.09.016 · Cited by 9
Frölich, J., Banaschewski, T., Spanagel, R., Döpfner, M., & Lehmkuhl, G. (2012) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000185 · Cited by 10
Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex
Huang, Z., Wei, X., Wang, Y., Tian, J., Dong, J., Liang, B., Lu, L., & Zhang, W. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00841 · Cited by 8
“Besides depressive disorders, it is well-established that the OFC is one of the most vulnerable brain regions in addiction [30,31] and obsessive-compulsive disorder [32,33], and current clinal trials showed that psilocybin and other psychedelics targeting 5-HT 2A receptor are effective for the…”
Metadata
- Authors
- Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., Burr, G., Cooper, T., & Wolf, A. P.
- Affiliations
- State University of New York (US)
- Brookhaven National Laboratory (US)
- Zucker Hillside Hospital (US)
- New York University (US)
- Northport VA Medical Center (US)
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 1994-04
- Volume
- 16
- Issue
- 4
- Pages
- 255-262
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2006715508
- Cited by
- 379
- References
- 68
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 5 · 2019: 8 · 2018: 2 · 2017: 9 · 2016: 6 · 2015: 13 · 2014: 16 · 2013: 12 · 2012: 12
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Synapse (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- National Institutes of Health (5p01ns015638-15)
- National Institute on Drug Abuse (NIDA 5RO1-DA06891, R01DA006891)
- National Institute of Neurological Disorders and Stroke (NINDS NS15638)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- endogenous dopamine, dopamine release, [11C]raclopride, dopamine D2 receptor, striatal dopamine, psychostimulants, age-related changes, mood, anxiety
- MeSH terms
- Adult, Affect, Anxiety, Basal Ganglia, Binding, Competitive, Brain, Brain Chemistry, Cerebrovascular Circulation, Dopamine, Humans, Male, Methylphenidate, Middle Aged, Salicylamides, Synapses, Tomography, Emission-Computed, Neostriatum, Raclopride, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.